Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Teduglutide (brand names Gattex in the US and Revestive in Europe) is a 33-membered polypeptide and glucagon-like peptide-2 (GLP-2) analog that is used for the treatment of short bowel syndrome.
According to Researcher's new survey, global Glucagon-like Peptide-2 (GLP-2) Agonist market is projected to reach US$ 2122.1 million in 2029, increasing from US$ 751 million in 2022, with the CAGR of 16.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Glucagon-like Peptide-2 (GLP-2) Agonist market research.
The Teduglutide market is primarily driven by the demand for innovative therapies to address short bowel syndrome (SBS) and improve the quality of life for affected patients. Teduglutide is a medication used to treat SBS, a condition characterized by impaired intestinal function due to surgical resection or congenital anomalies. The limited treatment options for SBS, coupled with advancements in gastrointestinal medicine and patient-centric care, contribute to market growth. Moreover, the demonstrated efficacy of Teduglutide in reducing dependence on parenteral nutrition and enhancing nutrient absorption further propels adoption. However, challenges include managing potential side effects and addressing patient access issues. Navigating regulatory approvals, optimizing treatment regimens, and ensuring long-term safety and efficacy are ongoing concerns. The market's success relies on continuous research in gastrointestinal disorders, collaborations between pharmaceutical manufacturers and gastroenterologists, and comprehensive patient education on the benefits and potential risks of Teduglutide treatment while addressing the evolving challenges associated with SBS management and treatment accessibility.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Glucagon-like Peptide-2 (GLP-2) Agonist market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Takeda Pharmaceuticals
Segment by Type
Gattex
Revestive
Segment by Application
Hospital
Pharmacy
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Glucagon-like Peptide-2 (GLP-2) Agonist report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
According to Researcher's new survey, global Glucagon-like Peptide-2 (GLP-2) Agonist market is projected to reach US$ 2122.1 million in 2029, increasing from US$ 751 million in 2022, with the CAGR of 16.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Glucagon-like Peptide-2 (GLP-2) Agonist market research.
The Teduglutide market is primarily driven by the demand for innovative therapies to address short bowel syndrome (SBS) and improve the quality of life for affected patients. Teduglutide is a medication used to treat SBS, a condition characterized by impaired intestinal function due to surgical resection or congenital anomalies. The limited treatment options for SBS, coupled with advancements in gastrointestinal medicine and patient-centric care, contribute to market growth. Moreover, the demonstrated efficacy of Teduglutide in reducing dependence on parenteral nutrition and enhancing nutrient absorption further propels adoption. However, challenges include managing potential side effects and addressing patient access issues. Navigating regulatory approvals, optimizing treatment regimens, and ensuring long-term safety and efficacy are ongoing concerns. The market's success relies on continuous research in gastrointestinal disorders, collaborations between pharmaceutical manufacturers and gastroenterologists, and comprehensive patient education on the benefits and potential risks of Teduglutide treatment while addressing the evolving challenges associated with SBS management and treatment accessibility.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Glucagon-like Peptide-2 (GLP-2) Agonist market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Takeda Pharmaceuticals
Segment by Type
Gattex
Revestive
Segment by Application
Hospital
Pharmacy
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Glucagon-like Peptide-2 (GLP-2) Agonist report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
